» Articles » PMID: 35859439

Replication of SARS-CoV-2 in Cell Lines Used in Public Health Surveillance Programmes with Special Emphasis on Biosafety

Overview
Specialty General Medicine
Date 2022 Jul 21
PMID 35859439
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Objectives: Polio, measles, rubella, influenza and rotavirus surveillance programmes are of great public health importance globally. Virus isolation using cell culture is an integral part of such programmes. Possibility of unintended isolation of SARS-CoV-2 from clinical specimens processed in biosafety level-2 (BSL-2) laboratories during the above-mentioned surveillance programmes, cannot be ruled out. The present study was conducted to assess the susceptibility of different cell lines to SARS-CoV-2 used in these programmes.

Methods: Replication of SARS-CoV-2 was studied in RD and L20B, Vero/hSLAM, MA-104 and Madin-Darby Canine Kidney (MDCK) cell lines, used for the isolation of polio, measles, rubella, rotavirus and influenza viruses, respectively. SARS-CoV-2 at 0.01 multiplicity of infection was inoculated and the viral growth was assessed by observation of cytopathic effects followed by real-time reverse transcription-polymerase chain reaction (qRT-PCR). Vero CCL-81 cell line was used as a positive control.

Results: SARS-CoV-2 replicated in Vero/hSLAM, and MA-104 cells, whereas it did not replicate in L20B, RD and MDCK cells. Vero/hSLAM, and Vero CCL-81 showed rounding, degeneration and detachment of cells; MA-104 cells also showed syncytia formation. In qRT-PCR, Vero/hSLAM and MA-104 showed 10 and Vero CCL-81 showed 10 viral RNA copies per μl. The 50 per cent tissue culture infectious dose titres of Vero/hSLAM, MA-104 and Vero CCL-81 were 10, 10 and 10/ml, respectively.

Interpretation & Conclusions: Replication of SARS-CoV-2 in Vero/hSLAM and MA-104 underscores the possibility of its unintended isolation during surveillance procedures aiming to isolate measles, rubella and rotavirus. This could result in accidental exposure to high titres of SARS-CoV-2, which can result in laboratory acquired infections and community risk, highlighting the need for revisiting biosafety measures in public health laboratories.

Citing Articles

Evaluation of the diagnostic accuracy of Xpert® Mpox and STANDARD™ M10 MPX/OPX for the detection of monkeypox virus.

Romero-Ramirez A, Somasundaran A, Kontogianni K, Parkes J, Hussain Y, Gould S J Infect. 2025; 90(2):106413.

PMID: 39824291 PMC: 11825380. DOI: 10.1016/j.jinf.2025.106413.


Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications.

Wooding D, Buist K, Romero-Ramirez A, Savage H, Watkins R, Bengey D mSphere. 2024; 9(11):e0030424.

PMID: 39412283 PMC: 11580409. DOI: 10.1128/msphere.00304-24.


Differential Cell Line Susceptibility to the SARS-CoV-2 Omicron BA.1.1 Variant of Concern.

Dighe H, Sarkale P, Patil D, Mohandas S, Shete A, Sahay R Vaccines (Basel). 2022; 10(11).

PMID: 36423057 PMC: 9696227. DOI: 10.3390/vaccines10111962.


SARS-CoV-2 air and surface contamination in residential settings.

Correia G, Rodrigues L, Afonso M, Mota M, Oliveira J, Soares R Sci Rep. 2022; 12(1):18058.

PMID: 36302823 PMC: 9610309. DOI: 10.1038/s41598-022-22679-y.

References
1.
Foladori P, Cutrupi F, Segata N, Manara S, Pinto F, Malpei F . SARS-CoV-2 from faeces to wastewater treatment: What do we know? A review. Sci Total Environ. 2020; 743:140444. PMC: 7311891. DOI: 10.1016/j.scitotenv.2020.140444. View

2.
Caly L, Druce J, Roberts J, Bond K, Tran T, Kostecki R . Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J Aust. 2020; 212(10):459-462. PMC: 7228321. DOI: 10.5694/mja2.50569. View

3.
Yin S, Zhou Z, Wang J, Deng Y, Jing H, Qiu Y . Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study. Virol J. 2021; 18(1):126. PMC: 8197603. DOI: 10.1186/s12985-021-01597-x. View

4.
Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H . SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021; 184(9):2362-2371.e9. PMC: 7901273. DOI: 10.1016/j.cell.2021.02.042. View

5.
Mendelsohn C, Johnson B, Lionetti K, Nobis P, Wimmer E, Racaniello V . Transformation of a human poliovirus receptor gene into mouse cells. Proc Natl Acad Sci U S A. 1986; 83(20):7845-9. PMC: 386819. DOI: 10.1073/pnas.83.20.7845. View